The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Patents, Royalties, Other Intellectual Property - I received royalities for authoring textbook chapters related to surgical pathology/medicine for Elsevier publishing company.
Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy.
 
Zofia Piotrowska
Consulting or Advisory Role - Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo Europe GmbH; Janssen; Jazz Pharmaceuticals; Takeda
Research Funding - Abbvie (Inst); ARIAD/Takeda (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline/Tesaro (Inst); Janssen Oncology (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune
 
Andrew Piper-Vallillo
Consulting or Advisory Role - Genzyme
 
Mandeep Banwait
No Relationships to Disclose
 
Yin P Hung
No Relationships to Disclose
 
Revati Rao
No Relationships to Disclose
 
Alona Muzikansky
No Relationships to Disclose
 
Catherine Belle Meador
No Relationships to Disclose
 
Aaron N. Hata
Consulting or Advisory Role - Engine Biosciences; Nuvalent, Inc.; TigaTx; Tolremo
Research Funding - Amgen (Inst); Blueprint Medicines (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Roche/Genentech (Inst); Scorpion Therapeutics (Inst)
 
Lecia V. Sequist
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Janssen Oncology; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Delfi Diagnostics (Inst); Genentech (Inst); Johnson & Johnson (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)